Intraocular pressure after intravitreal injection of triamcinolone acetonide

被引:286
作者
Jonas, JB [1 ]
Kreissig, I [1 ]
Degenring, R [1 ]
机构
[1] Univ Heidelberg, Augenklin, Fac Clin Med Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany
关键词
D O I
10.1136/bjo.87.1.24
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aim: To investigate the intraocular pressure (IOP) response after intravitreal injections of triamcinolone acetonide as treatment of intraocular neovascular or oedematous diseases. Methods: The prospective consecutive non-comparative interventional case series study included 71 patients (75 eyes) with progressive exudative age related macular degeneration (n=64 eyes) or diffuse diabetic macular oedema (n=11 eyes), who received an intravitreal injection of 25 mg triamcinolone acetonide. Mean follow up time was 6.86 (SD 2.52) months (range 3.1-14.47 months). Results: IOP increased significantly (p<0.001) from 15.43 (3.26) mm Hg preoperatively to a mean maximum of 23.38 (8.37) mm Hq (range 13-64 mm Hg) postoperatively. An IOP rise to values higher than 21 mm Hg was observed in 39 (52%) eyes. Elevation of IOP occurred about 2 months after the injection. Preoperative predictive factor for the rise in IOP was younger age (p=0.013). It was statistically independent of refractive error, presence of diabetes mellitus, and indication for the injection. In all but one eye, IOP could be lowered to the normal range with topical medication, without development of glaucomatous optic nerve head changes. In the eyes with an elevation of IOP, IOP normalised about 6 months after the injection, without further medication. Eyes undergoing repeatedly intravitreal injections of triamcinolone acetonide showed only an elevation of IOP, if after the first injection a rise of IOP had occurred. Conclusions: After intravitreal injections of 25 mg of triamcinolone acetonide, an IOP elevation can develop in about 50% of eyes, starting about 1-2 months after the injection. In the vast majority, IOP can be normalised by topical medication, and returns to normal values without further medication about 6 months after the injection.
引用
收藏
页码:24 / 27
页数:4
相关论文
共 42 条
[1]   Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study [J].
Antcliff, RJ ;
Spalton, DJ ;
Stanford, MR ;
Graham, EM ;
Ffytche, TJ ;
Marshall, J .
OPHTHALMOLOGY, 2001, 108 (04) :765-772
[2]   THE EFFECTS OF INTRAVITREAL TRIAMCINOLONE ACETONIDE ON EXPERIMENTAL PRERETINAL NEOVASCULARIZATION [J].
ANTOSZYK, AN ;
GOTTLIEB, JL ;
MACHEMER, R ;
HATCHELL, DL .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1993, 231 (01) :34-40
[3]  
BECKER B, 1965, ARCH OPHTHALMOL-CHIC, V74, P621
[4]  
BECKER B, 1966, ARCH OPHTHALMOL-CHIC, V76, P477
[5]  
Berger AS, 1996, INVEST OPHTH VIS SCI, V37, P2318
[6]  
BIGGER JF, 1972, NEW ENGL J MED, V287, P992
[7]   Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up [J].
Challa, JK ;
Gillies, MC ;
Penfold, PL ;
Gyory, JF ;
Hunyor, ABL ;
Billson, FA .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, 1998, 26 (04) :277-281
[8]   Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model [J].
Ciulla, TA ;
Criswell, MH ;
Danis, RP ;
Hill, TE .
ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (03) :399-404
[9]   Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide [J].
Danis, RP ;
Bingaman, DP ;
Yang, YS ;
Ladd, B .
OPHTHALMOLOGY, 1996, 103 (12) :2099-2104
[10]  
Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004